

Dementia Curriculum for Health Care Professionals

Module 15: References

Role of the Pharmacist in the Care of Persons Living with Dementia



Module 15 References

Alexopoulos, G.S. (1996). The treatment of depressed outpatients. *Journal of Clinical Psychiatry*, 57(suppl 14), 14-20.

Allgaier, M., & Allgaier, C. (2013). An update on drug treatment options of Alzheimer's disease. *Frontiers in bioscience (Landmark edition)*, 19, 1345-1354.

Alternative Treatments. (2016). Retrieved from <https://www.alz.org/alzheimers-dementia/treatments/alternative-treatments>

Alzheimer's and Dementia Caregiver Center. Sleep Issues and Sundowning. (2016). Retrieved from <http://www.alz.org/care/alzheimers-dementia-sleep-issues-sundowning.asp>.

Alzheimer's Disease (2014, April). Retrieved from <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/alzheimers-disease/>.

Alzheimer's Disease and Sleep. (2016). Retrieved from <https://www.sleepfoundation.org/sleep-disorders-problems/alzheimers-disease-and-sleep>

Alzheimer's Disease Genetics Fact Sheet. (2016, August 18). Retrieved from <https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-genetics-fact-sheet>.

Alzheimer's Disease: Unraveling the Mystery. National Institutes of Health. (2008, Sept). Retrieved from https://d2cauhfh6h4x0p.cloudfront.net/s3fs-public/alzheimers_disease_unraveling_the_mystery_2.pdf?k0OsljJHDyFRrRXL78dV_YsOeNlvba_w1.

Alzheimer's Research on Causes and Risk Factors, (2016). Retrieved from <https://www.alzinfo.org/articles/what-causes-alzheimers/>.

Birks, J. S. (2006). Cholinesterase inhibitors for Alzheimer's disease. *The Cochrane Library*.

Bohnen, N. I., Kaufer, D. I., Hendrickson, R., Ivanco, L. S., Lopresti, B., Davis, J. G., ... & DeKosky, S. T. (2005). Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. *Neuroscience letters*, 380(1), 127-132.

Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008). Impact of anticholinergics on the aging brain: a review and practical application.

Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H. M. (2007). O1-02-01: Forecasting the global prevalence and burden of Alzheimer's disease. *Alzheimer's & Dementia*, 3(3), S168.

Cantú, T. G., & Korek, J. S. (1991). Central nervous system reactions to histamine-2 receptor blockers. *Annals of internal medicine*, 114(12), 1027-1034.

Carnahan, R. M., Lund, B. C., Perry, P. J., Pollock, B. G., & Culp, K. R. (2006). The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. *The Journal of Clinical Pharmacology*, *46*(12), 1481-1486.

Caro, J., Salas, M., Ward, A., Getsios, D., Migliaccio-Walle, K., & Garfield, F. (2004). Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. *Drugs & aging*, *21*(10), 677-686.

Chew, M. L., Mulsant, B. H., Pollock, B. G., Lehman, M. E., Greenspan, A., Mahmoud, R. A., ... & Gharabawi, G. (2008). Anticholinergic activity of 107 medications commonly used by older adults. *Journal of the American Geriatrics Society*, *56*(7), 1333-1341.

Child, A., Clarke, A., Fox, C., & Maidment, I. (2012). A pharmacy led program to review anti-psychotic prescribing for people with dementia. *BMC psychiatry*, *12*(1), 1.

Ciriaco, M., Ventrice, P., Russo, G., Scicchitano, M., Mazzitello, G., Scicchitano, F., & Russo, E. (2013). Corticosteroid-related central nervous system side effects. *Journal of Pharmacology and Pharmacotherapeutics*, *4*(5), 94.

Dantoine, T., Auriacombe, S., Sarazin, M., Becker, H., Pere, J. J., & Bourdeix, I. (2006). Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. *International journal of clinical practice*, *60*(1), 110-118.

DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., ... & Kuller, L. H. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. *JAMA*, *300*(19), 2253-2262.

Dementia Including Alzheimer's Disease. (2016). Retrieved from <https://www.bladderandbowelfoundation.org/bladder/bladder-conditions-and-symptoms/alzheimers-and-incontinence/>.

DeSimone II, E. M., & Viereck, L. (2011). Alzheimer's Disease: Increasing Numbers, But No Cure-Although no medications are available that can reverse the progress of the disorder, a number of drugs have limited utility in treating cognitive symptoms. *US Pharmacist*, *36*(1), 26.

Diagnosis of Alzheimer's Disease and Dementia. (2016). Retrieved from http://www.alz.org/alzheimers_disease_diagnosis.asp.

Donepezil package insert. (2015, July). Retrieved from <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/surveillance/drugmarketingadvertisingandcommunications/ucm368444.pdf>.

Dotson, V. M., Beydoun, M. A., & Zonderman, A. B. (2010). Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. *Neurology*, 75(1), 27-34.

Efjestad, A. S., Molden, E., & Øksengård, A. R. (2013). Pharmacist-Initiated Management of Antagonistic Interactions between Anticholinergic Drugs and Acetyl cholinesterase Inhibitors in Individuals with Dementia. *Journal of the American Geriatrics Society*, 61(9), 1624-1625.

Farlow, M. R., Salloway, S., Tariot, P. N., Yardley, J., Moline, M. L., Wang, Q., ... & Satlin, A. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. *Clinical therapeutics*, 32(7), 1234-1251.

Feinberg, M. V., & Michocki, R. J. (1998). Clinical and regulatory concerns in Alzheimer's disease management: Role of the pharmacist. *American journal of health-system pharmacy*, 55(suppl 2), S26-S31.

Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Hux, M., Xu, Y., ... & Mastey, V. (2004). Economic evaluation of donepezil in moderate to severe Alzheimer disease. *Neurology*, 63(4), 644-650.

Francis, P. T., Parsons, C. G., & Jones, R. W. (2012). Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. *Expert review of neurotherapeutics*, 12(11), 1351-1365.

Galantamine package insert. (2015, December). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021615lbl.pdf.

Gardette, V., Andrieu, S., Lapeyre-Mestre, M., Coley, N., Cantet, C., Ousset, P. J., ... & Vellas, B. (2010). Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease. *CNS drugs*, 24(5), 431-442.

Gellad, W. F., Grenard, J. L., & Marcum, Z. A. (2011). A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. *The American journal of geriatric pharmacotherapy*, 9(1), 11-23.

Geriatric Depression Scale. (2016). Retrieved from <https://web.stanford.edu/~yesavage/GDS.html>.

Green, C. (2007). Modelling disease progression in Alzheimer's disease. *Pharmacoeconomics*, 25(9), 735-750.

Hauber, A. B., Gnanasakthy, A., Snyder, E. H., Bala, M. V., Richter, A., & Mauskopf, J. A. (2000). Potential savings in the cost of caring for Alzheimer's disease. *Pharmacoeconomics*, 17(4), 351-360.

Han, L., Agostini, J. V., & Allore, H. G. (2008). Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. *Journal of the American Geriatrics Society*, 56(12), 2203-2210.

Hernandez, R. K., Farwell, W., Cantor, M. D., & Lawler, E. V. (2009). Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. *Journal of the American Geriatrics Society*, 57(11), 1997-2003.

Kroner, Z. (2009). The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?. *Alternative Medicine Review*, 14(4), 373.

Larson, E. B., Reifler, B. V., Featherstone, H. J., & English, D. R. (1984). Dementia in elderly outpatients: a prospective study. *Annals of internal medicine*, 100(3), 417-423.

Levin, G. (2005). The pharmacist's role in identifying patients at risk for Alzheimer's disease. *Review*, 3, 136-145.

Lieberman, J. A. (2004). Managing anticholinergic side effects. *Prim Care Companion J Clin Psychiatry*, 6(Suppl 2), 20-23.

Livingston, G., & Katona, C. (2004). The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. *International journal of geriatric psychiatry*, 19(10), 919-925.

Lonn, E., Bosch, J., Yusuf, S., Sheridan, P., Pogue, J., Arnold, J. M., ... & Dagenais, G. R. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. *JAMA*, 293(11), 1338-1347.

Marasco, R., Heely, J. A., & Gardner, M. (2002). The pharmacist's role in managing patients with Alzheimer's disease. *Journal of the American Pharmacists Association: JAPhA*, 43(5 Suppl 1), S20-1.

McGuffey, E. C. (1997). Alzheimer's Disease: An Overview for the Pharmacist: This debilitating disorder affects up to 3.5 times more women than men. *Journal of the American Pharmaceutical Association (1996)*, 37(3), 347-352.

McGuinness, B., Bullock, R., Craig, D., Kerr, E., & Passmore, P. (2009). Statins for the treatment of Alzheimer's disease and dementia. *The Cochrane Library*.

McKercher, P. L., Taylor, S. D., Lee, J. A., Chao, J., & Kumar, R. N. (2003). Prescription drug use among elderly and nonelderly families. *Journal of Managed Care Pharmacy*, 9(1), 19-28.

Memantine package insert. (2013, October). Retrieved from <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9f27baf-aa2a-443a-9ef5-e002d23407ba>.

Migliaccio-Walle, K., Getsios, D., Caro, J. J., Ishak, K. J., O'Brien, J. A., Papadopoulos, G., & AHEAD Study Group. (2003). Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. *Clinical therapeutics*, 25(6), 1806-1825.

Mild Cognitive Impairment. (2016). Retrieved from https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-impairment

Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005). Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Annals of internal medicine*, 142(1), 37-46.

Mölsä, P. K., Marttila, R. J., & Rinne, U. K. (1986). Survival and cause of death in Alzheimer's disease and multi-infarct dementia. *Acta Neurologica Scandinavica*, 74(2), 103-107.

Needy Meds. (2016). Retrieved from <http://www.needymeds.org/>.

Neugroschl, J., & Wang, S. (2011). Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity. *Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine*, 78(4), 596-612.

Parnetti, L., Amici, S., Lanari, A., & Gallai, V. (2001). Pharmacological treatment of non-cognitive disturbances in dementia disorders. *Mechanisms of ageing and development*, 122(16), 2063-2069.

Pouryamout, L., Dams, J., Wasem, J., & Dodel, R. (2012). Economic Evaluation of Treatment Options in Patients with Alzheimer's Disease. *Drugs*, 72(6), 789-802.

Rabins, P. V., Blacker, D., Rovner, B. W., Rummans, T. A., Schneider, L. S., Tariot, P. N., ... & Cook, I. A. (2007). American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. *The American journal of psychiatry*, 164(12 Suppl), 5-56.

Radcliff, S., Yue, J., Rocco, G., Aiello, S. E., Ickowicz, E., Hurd, Z., ... & Beers, M. H. (2015). American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. *Journal of the American Geriatrics Society*, 63(11), 2227-2246.

Rivastigmine package insert. (2015, February). Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf.

Rosenberg, P. B., Mielke, M. M., Xue, Q. L., & Carlson, M. C. (2010). Depressive symptoms predict incident cognitive impairment in cognitive healthy older women. *The American Journal of Geriatric Psychiatry*, 18(3), 204-211.

Rosenberg, P. B., Mielke, M. M., Appleby, B., Oh, E., Leoutsakos, J. M., & Lyketsos, C. G. (2011). Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. *International journal of geriatric psychiatry*, 26(4), 364-372.

Rudolph, J. L., Salow, M. J., Angelini, M. C., & McGlinchey, R. E. (2008). The anticholinergic risk scale and anticholinergic adverse effects in older persons. *Archives of internal medicine*, 168(5), 508-513.

Saczynski, J. S., Beiser, A., Seshadri, S., Auerbach, S., Wolf, P. A., & Au, R. (2010). Depressive symptoms and risk of dementia The Framingham Heart Study. *Neurology*, 75(1), 35-41.

Sadowsky, C., Perez, J. A., Bouchard, R. W., Goodman, I., & Tekin, S. (2010). Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. *CNS neuroscience & therapeutics*, 16(1), 51-60.

Savva, G. M., Zaccai, J., Matthews, F. E., Davidson, J. E., McKeith, I., & Brayne, C. (2009). Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. *The British Journal of Psychiatry*, 194(3), 212-219.

Schneider, L. S., Dagerman, K., & Insel, P. S. (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *The American Journal of Geriatric Psychiatry*, 14(3), 191-210.

Schneider, L. S., Dagerman, K. S., Higgins, J. P., & McShane, R. (2011). Lack of evidence for the efficacy of memantine in mild Alzheimer disease. *Archives of neurology*, 68(8), 991-998.

Shumaker, S. A., Legault, C., Kuller, L., Rapp, S. R., Thal, L., Lane, D. S., ... & Masaki, K. (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*, 291(24), 2947-2958.

Skelton, J. B. (2008). White paper on expanding the role of pharmacists in caring for individuals with Alzheimer's disease. *Journal of the American Pharmacists Association: JAPhA*, 48(6).

Svendsboe, E., Terum, T., Testad, I., Aarsland, D., Ulstein, I., Corbett, A., & Rongve, A. (2016). Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease. *International journal of geriatric psychiatry*.

Swallowing Disorders (Dysphagia) in Adults. (2016). Retrieved from <https://www.asha.org/public/speech/swallowing/Swallowing-Disorders-in-Adults/>

Tan, C. C., Yu, J. T., Wang, H. F., Tan, M. S., Meng, X. F., Wang, C., ... & Tan, L. (2014). Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. *Journal of Alzheimer's Disease*, 41(2), 615-631

Tett, S. E., Higgins, G. M., & Armour, C. L. (1993). Impact of pharmacist interventions on medication management by the elderly: a review of the literature. *Annals of Pharmacotherapy*, 27(1), 80-86.

The Montreal Cognitive Assessment. (2016). Retrieved from <http://www.mocatest.org/>.

U.S. Pharmacopeial Convention. USP Pictograms. (2016). Retrieved from <http://www.usp.org/health-quality-safety/usp-pictograms>

Versijpt, J. (2014). Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia. *Journal of Alzheimer's Disease*, 42(s3), S19-S25.

Veterans Administration/ Saint Louis University Mental Status exam (2016). Retrieved from <https://www.slu.edu/medicine/internal-medicine/geriatric-medicine/aging-successfully/assessment-tools/mental-status-exam.php>

Wang, J., Yu, J. T., Wang, H. F., Meng, X. F., Wang, C., Tan, C. C., & Tan, L. (2014). Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. *Journal of Neurology, Neurosurgery & Psychiatry*, jnnp-2014.

Wiens, C. The challenges of medication management in patients with Alzheimer's disease. *The Canadian Alzheimer's Disease Review*. (2003). Retrieved from http://www.stacommunications.com/customcomm/Back-issue_pages/AD_Review/adPDFs/september2003/16.pdf

Wollen, K. A. (2010). Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. *Altern. Med. Rev*, 15(3), 223-244.

Yang, M., Xu, D. D., Zhang, Y., Liu, X., Hoeven, R., & Cho, W. C. S. (2014). A systematic review on natural medicines for the prevention and treatment of Alzheimer's disease with meta-analyses of intervention effect of ginkgo. *The American journal of Chinese medicine*, 42(03), 505-521.

Zagaria, M.A. (2011). Predisposition to infection in the elderly. *US Pharmacist*, 36, 28-31

Module 15 Resources

This list of resources has been identified by HRSA, the expert panel, and a literature search to help guide health care professionals and primary care providers provide assistance to persons with dementia and their care partners.

Alzheimer's Association

<http://www.alz.org>

1-800-272-3900 (toll-free)

1-866-403-3073 (TDD/toll-free)

Alzheimer's Disease (Centers for Disease Control and Prevention)_Retrieved from

<http://www.cdc.gov/aging/aginginfo/alzheimers.htm>

Alzheimer's Disease Education and Referral (ADEAR) Center Retrieved from

<https://www.nia.nih.gov/health/alzheimers>

1-800-438-4380 (toll-free)

Alzheimer's Foundation of America

Retrieved from <https://alzfdn.org/>

1-866-AFA-8484 (1-866-232-8484; toll-free)

Association for Frontotemporal Degeneration

Retrieved from

<http://www.theaftd.org/>

1-866-507-7222

Brain Health Resource

Retrieved from

<http://www.nia.nih.gov/health/publication/brain-health-resource>

This presentation toolkit offers current, evidence-based information and resources to facilitate conversations with older people about brain health. Designed for use at senior centers and in other community settings, it contains a PowerPoint presentation, an educator guide, handouts, and a resource list. Materials are written in plain language and explain what people can do to help keep their brains functioning best as they age.

Centers for Disease Control and Prevention

Retrieved from

<http://www.cdc.gov/aging/aginginfo/alzheimers.htm>

Lewy Body Dementia Association Retrieved from <http://www.lbda.org/node/7>
1-404-935-6444

National Parkinson Foundation
Retrieved from <http://www.Parkinson.org>
1-800-473-4636

The Dementias: Hope Through Research
Retrieved from <http://www.nia.nih.gov/alzheimers/publication/dementias/introduction>